Insights

Let’s start with a number that should make any pharmaceutical strategist put down their coffee: analysts project that emerging markets […]

Executive Summary Engaging a contract development and manufacturing organization (CDMO) has gone from tactical cost arbitrage to board-level strategic decision.

Executive Briefing: Pricing Is Not an Art, It’s an IP-Driven War Let’s be blunt. Setting the launch price for a

The premise sounds straightforward enough: a blockbuster biologic loses patent protection, a competitor copies it at lower cost, patients save

Section 1: The Economics Nobody Talks About Generic drugs fill roughly 90% of all U.S. prescriptions while accounting for only

A deep-dive for pharma IP teams, portfolio managers, R&D leads, and institutional investors Executive Summary The generic pharmaceutical industry is

Defining a Blockbuster Drug in 2026 — and Why the Definition Is Shifting The pharmaceutical industry has operated with a

A deep dive into patent cliffs, IP valuation, biosimilar development roadmaps, complex generics portfolios, and the regulatory playbooks that will

Part I: The Economics of Generic Entry — Why the Old Model Is Broken The Scale of the Industry and